Cdx genes, inflammation and the pathogenesis of Barrett's metaplasia

Trends in Molecular Medicine

Volumn 15, Issue 7, 2009, Pages 313-322

  Colleypriest, Benjamin J ^a   Palmer, Rebecca M ^a   Ward, Stephen G ^a   Tosh, David ^a  

^a University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GAMMA INTERFERON; GASTRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTON PUMP INHIBITOR; RANTES; RETINOIC ACID; TRANSCRIPTION FACTOR CDX1; TRANSCRIPTION FACTOR CDX2;

BARRETT ESOPHAGUS; CANCER GROWTH; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; DISEASE COURSE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; GASTRIN BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION; GENETIC POLYMORPHISM; HISTOLOGY; HUMAN; MONOCYTE; NONHUMAN; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE;

ANIMALS; BARRETT ESOPHAGUS; GENE EXPRESSION; HOMEODOMAIN PROTEINS; HUMANS; METAPLASIA; NEOPLASMS;

EID: 67649880329     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2009.05.001     Document Type: Review

References (101)

1. Quinlan J.M., et al. Epithelial metaplasia and the development of cancer. Biochim. Biophys. Acta 1776 (2007) 10-21
2. Tosh D., and Slack J.M. How cells change their phenotype. Nat. Rev. Mol. Cell Biol. 3 (2002) 187-194
3. Conio M., et al. Risk factors for Barrett's esophagus: a case-control study. Int. J. Cancer 97 (2002) 225-229
4. Hussain S.P., and Harris C.C. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer 121 (2007) 2373-2380
5. Devesa S.S., et al. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
6. Shaheen N.J., et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology 119 (2000) 333-338
7. Wild C.P., and Hardie L.J. Reflux Barrett's oesophagus and adenocarcinoma: burning questions. Nat. Rev. Cancer 3 (2003) 676-684
8. van Soest E.M., et al. Increasing incidence of Barrett's oesophagus in the general population. Gut 54 (2005) 1062-1066
9. El-Serag H.B., et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am. J. Gastroenterol. 99 (2004) 1877-1883
10. Carlson N., et al. Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation. Am. J. Gastroenterol. 97 (2002) 1340-1345
11. Garcia Rodriguez L.A., et al. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 55 (2006) 1538-1544
12. Haigh C.R., et al. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 124 (2003) 615-625
13. Yu W.Y., et al. Conversion of columnar to stratified squamous epithelium in the developing mouse oesophagus. Dev. Biol. 284 (2005) 157-170
14. Leedham S.J., et al. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut 57 (2008) 1041-1048
15. Slack J.M. Stem cells in epithelial tissues. Science 287 (2000) 1431-1433
16. Fitzgibbons P.L., et al. Prevalence of gastric metaplasia, inflammation, and Campylobacter pylori in the duodenum of members of a normal population. Am. J. Clin. Pathol. 90 (1988) 711-714
17. Kundu J.K., and Surh Y.J. Inflammation: gearing the journey to cancer. Mutat. Res. 659 (2008) 15-30
18. El-Omar E.M., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404 (2000) 398-402
19. Sun J., et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J. Natl. Cancer Inst. 97 (2005) 525-532
20. Arnott C.H., et al. Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development. Oncogene 23 (2004) 1902-1910
21. Cerhan J.R., et al. Genetic variation in tumor necrosis factor and the nuclear factor-κB canonical pathway and risk of non-Hodgkin's lymphoma. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 3161-3169
22. Sadeghi S., et al. Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 1169-1178
23. Corley D.A., et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124 (2003) 47-56
24. de Caestecker, J. and Jankowski, J. A phase III, randomised study of aspirin and esoprazole chemoprevention in Barrett's metaplasia. In: OCTO; 2009
25. Moons L.M., et al. Barrett's oesophagus is characterized by a predominantly humoral inflammatory response. J. Pathol. 207 (2005) 269-276
26. Fitzgerald R.C., et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 50 (2002) 451-459
27. Roth K.A., et al. Cellular immune responses are essential for the development of Helicobacter felis-associated gastric pathology. J. Immunol. 163 (1999) 1490-1497
28. Smythies L.E., et al. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice. J. Immunol. 165 (2000) 1022-1029
29. Eaton K.A., et al. The role of T cell subsets and cytokines in the pathogenesis of Helicobacter pylori gastritis in mice. J. Immunol. 166 (2001) 7456-7461
30. Vaezi M.F., and Richter J.E. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 111 (1996) 1192-1199
31. Jankowski J.A., et al. Barrett's metaplasia. Lancet 356 (2000) 2079-2085
32. Neugut A.I., et al. The epidemiology of cancer of the small bowel. Cancer Epidemiol. Biomarkers Prev. 7 (1998) 243-251
33. O'Riordan J.M., et al. Proinflammatory cytokine and nuclear factor κ-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am. J. Gastroenterol. 100 (2005) 1257-1264
34. Fitzgerald R.C., et al. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 51 (2002) 316-322
35. Hayden M.S., and Ghosh S. Signaling to NF-κB. Genes Dev. 18 (2004) 2195-2224
36. Dvorakova K., et al. Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin. Cancer Res. 10 (2004) 2020-2028
37. Dvorak K., et al. Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to barrett's esophagus. Clin. Cancer Res. 13 (2007) 5305-5313
38. Dannenberg A.J., et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2 (2001) 544-551
39. Kandil H.M., et al. Cyclooxygenase-2 expression in Barrett's esophagus. Dig. Dis. Sci. 46 (2001) 785-789
40. Ferguson H.R., et al. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 727-731
41. Morris C.D., et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am. J. Gastroenterol. 96 (2001) 990-996
42. Harris R.E., et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol. Rep. 13 (2005) 559-583
43. Oyama K., et al. Nippon Shokakibyo Gakkai Zasshi 104 (2007) 1183-1191
44. Buttar N.S., et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 122 (2002) 1101-1112
45. Zhang F., et al. Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology 121 (2001) 1391-1399
46. Song S., et al. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma. Gut 56 (2007) 1512-1521
47. Hamaguchi M., et al. Increased expression of cytokines and adhesion molecules in rat chronic esophagitis. Digestion 68 (2003) 189-197
48. Hamoui N., et al. Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus. Arch. Surg. 139 (2004) 712-716
49. Stairs D.B., et al. Cdx1 and c-Myc foster the initiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett's esophagus. PLoS One 3 (2008) e3534
50. Wong N.A., et al. CDX1 is an important molecular mediator of Barrett's metaplasia. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 7565-7570
51. Eda A., et al. Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. J. Gastroenterol. 38 (2003) 14-22
52. Bai Y.Q., et al. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett. 176 (2002) 47-55
53. Kozuka S., and Hachisuka K. Incidence by age and sex of intestinal metaplasia in the gallbladder. Hum. Pathol. 15 (1984) 779-784
54. Kozuka S., et al. Significance of intestinal metaplasia for the evolution of cancer in the biliary tract. Cancer 54 (1984) 2277-2285
55. Osawa H., et al. Aberrant expression of CDX2 in the metaplastic epithelium and inflammatory mucosa of the gallbladder. Am. J. Surg. Pathol. 28 (2004) 1253-1254
56. Steininger H., et al. Aberrant expression of CDX2 in metaplastic and inflammatory epithelium of the urinary bladder. Am. J. Surg. Pathol. 29 (2005) 1252
57. Tatematsu M., et al. Intestinal metaplasia as a common option of oval cells in relation to cholangiofibrosis in liver of rats exposed to 2-acetylaminofluorene. Lab. Invest. 52 (1985) 354-362
58. Albores-Saavedra J., et al. Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas. Ann. Diagn. Pathol. 11 (2007) 3-9
59. Zen Y., et al. Lipopolysaccharide induces overexpression of MUC2 and MUC5AC in cultured biliary epithelial cells: possible key phenomenon of hepatolithiasis. Am. J. Pathol. 161 (2002) 1475-1484
60. Moons L.M., et al. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J. Clin. Pathol. 57 (2004) 1063-1068
61. Silberg D.G., et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 122 (2002) 689-696
62. Mutoh H., et al. Conversion of gastric mucosa to intestinal metaplasia in Cdx2-expressing transgenic mice. Biochem. Biophys. Res. Commun. 294 (2002) 470-479
63. Mutoh H., et al. Cdx2 specifies the differentiation of morphological as well as functional absorptive enterocytes of the small intestine. Int. J. Dev. Biol. 49 (2005) 867-871
64. Kong J., et al. Induction of intestinalization in human esophageal keratinocytes is a multi-step process. Carcinogenesis 30 (2009) 122-130
65. Kazumori H., et al. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium. Gut 55 (2006) 16-25
66. Hu Y., et al. The pathogenesis of Barrett's esophagus: secondary bile acids upregulate intestinal differentiation factor CDX2 expression in esophageal cells. J. Gastrointest. Surg. 11 (2007) 827-834
67. Marchetti M., et al. Chronic acid exposure leads to activation of the cdx2 intestinal homeobox gene in a long-term culture of mouse esophageal keratinocytes. J. Cell Sci. 116 (2003) 1429-1436
68. Crabbe T., et al. The PI3K inhibitor arsenal: choose your weapon!. Trends Biochem. Sci. 32 (2007) 450-456
69. Kim S., et al. PTEN and TNF-α regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-κB-dependent pathway. Gastroenterology 123 (2002) 1163-1178
70. Benahmed F., Gross I., Gaunt S.J., et al. Multiple regulatory regions control the complex expression pattern of the mouse Cdx2 homeobox gene. Gastroenterology 135 (2008) 1238-1247
71. Saegusa M., et al. A functional role of Cdx2 in β-catenin signaling during trans-differentiation in endometrial carcinomas. Carcinogenesis 28 (2007) 1885-1892
72. Pacheco I.I., and Macleod R.J. CaSR stimulates secretion of Wnt5a from colonic myofibroblasts to stimulate CDX2 and sucrase-isomaltase using Ror2 on intestinal epithelia. Am. J. Physiol. Gastrointest. Liver Physiol. 295 (2008) G748-G759
73. Kazumori H., et al. Roles of caudal-related homeobox gene Cdx1 in oesophageal epithelial cells in Barrett's epithelium development. Gut 58 (2009) 620-628
74. Que J., et al. Morphogenesis of the trachea and esophagus: current players and new roles for noggin and Bmps. Differentiation 74 (2006) 422-437
75. Li Y., et al. Bmp4 is required for tracheal formation: a novel mouse model for tracheal agenesis. Dev. Biol. 322 (2008) 145-155
76. Milano F., et al. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology 132 (2007) 2412-2421
77. Lengerke C., et al. BMP and Wnt specify hematopoietic fate by activation of the Cdx-Hox pathway. Cell Stem Cell 2 (2008) 72-82
78. Barros R., et al. Key elements of the BMP/SMAD pathway co-localize with CDX2 in intestinal metaplasia and regulate CDX2 expression in human gastric cell lines. J. Pathol. 215 (2008) 411-420
79. White R.J., et al. Complex regulation of cyp26a1 creates a robust retinoic acid gradient in the zebrafish embryo. PLoS Biol. 5 (2007) e304
80. Fuchs E., and Raghavan S. Getting under the skin of epidermal morphogenesis. Nat. Rev. Genet. 3 (2002) 199-209
81. Chang C.L., et al. Retinoic acid-induced glandular differentiation of the oesophagus. Gut 56 (2007) 906-917
82. Radominska-Pandya A., and Chen G. Photoaffinity labeling of human retinoid X receptor β(RXRβ) with 9-cis-retinoic acid: identification of phytanic acid, docosahexaenoic acid, and lithocholic acid as ligands for RXRβ. Biochemistry 41 (2002) 4883-4890
83. Cooke G., et al. The effect of retinoic acid and deoxycholic acid on the differentiation of primary human esophageal keratinocytes. Dig. Dis. Sci. 53 (2008) 2851-2857
84. Bastien J., et al. The phosphoinositide 3-kinase/Akt pathway is essential for the retinoic acid-induced differentiation of F9 cells. Oncogene 25 (2006) 2040-2047
85. Greten F.R., et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
86. Ikeda H., et al. Interaction of Toll-like receptors with bacterial components induces expression of CDX2 and MUC2 in rat biliary epithelium in vivo and in culture. Lab. Invset. 87 (2007) 559-571
87. Ikeda H., et al. Tumor necrosis factor-α induces the aberrant expression of mucus core protein-2 in non-neoplastic biliary epithelial cells via the upregulation of CDX2 in chronic cholangitis. Hepatol. Res. 38 (2008) 1006-1017
88. Lin J., et al. Induction of mucin gene expression in middle ear of rats by tumor necrosis factor-α: potential cause for mucoid otitis media. J. Infect. Dis. 182 (2000) 882-887
89. Levine S.J., et al. Tumor necrosis factor-α induces mucin hypersecretion and MUC-2 gene expression by human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 12 (1995) 196-204
90. Li J.D., et al. Transcriptional activation of mucin by Pseudomonas aeruginosa lipopolysaccharide in the pathogenesis of cystic fibrosis lung disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 967-972
91. Li J.D., et al. Activation of NF-κB via a Src-dependent Ras-MAPK-pp90rsk pathway is required for Pseudomonas aeruginosa-induced mucin overproduction in epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 5718-5723
92. Escaffit F., et al. Cdx2 modulates proliferation in normal human intestinal epithelial crypt cells. Biochem. Biophys. Res. Commun. 342 (2006) 66-72
93. Olliver J.R., et al. DNA damage levels are raised in Barrett's oesophageal mucosa relative to the squamous epithelium of the oesophagus. Biomarkers 8 (2003) 509-521
94. Chen X., et al. Effects of vitamin E and selenium supplementation on esophageal adenocarcinogenesis in a surgical model with rats. Carcinogenesis 21 (2000) 1531-1536
95. Piazuelo E., et al. Superoxide dismutase prevents development of adenocarcinoma in a rat model of Barrett's esophagus. World J. Gastroenterol. 11 (2005) 7436-7443
96. Shishodia S., et al. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-κB activation through inhibition of IκBα kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 24 (2003) 1269-1279
97. Tselepis C., et al. Tumour necrosis factor-α in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 21 (2002) 6071-6081
98. Marshall H., et al. Retinoids and Hox genes. FASEB J. 10 (1996) 969-978
99. Seery J.P. Stem cells of the oesophageal epithelium. J. Cell Sci. 115 (2002) 1783-1789
100. Glickman J.N., et al. Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett's esophagus. Am. J. Surg. Pathol. 25 (2001) 569-578
101. Miyashita T., et al. Duodenal juice stimulates oesophageal stem cells to induce Barrett's oesophagus and oesophageal adenocarcinoma in rats. Oncol. Rep. 15 (2006) 1469-1475